SONEDENOSON

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H20ClN5O5
Molecular Weight	421.835
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC(OCCC2=CC=C(Cl)C=C2)=NC3=C1N=CN3[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O

InChI

InChIKey=WUCQGGOGHZRELS-LSCFUAHRSA-N

InChI=1S/C18H20ClN5O5/c19-10-3-1-9(2-4-10)5-6-28-18-22-15(20)12-16(23-18)24(8-21-12)17-14(27)13(26)11(7-25)29-17/h1-4,8,11,13-14,17,25-27H,5-7H2,(H2,20,22,23)/t11-,13-,14-,17-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C18H20ClN5O5
Molecular Weight	421.835
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://adisinsight.springer.com/drugs/800012525 | https://www.pharmacodia.com/yaodu/html/v1/chemicals/11b7f61a5eba9553137a47806ee56d36.html | https://www.ncbi.nlm.nih.gov/pubmed/22111533

Sonedenoson (MRE0094) is a topical adenosine A2A-receptor agonist which was under clinical development for the treatment of for diabetic foot ulcer. The compound was originally developed by New York University, and licensed to Medco Research (King Pharmaceuticals). King Pharmaceuticals was acquired by Pfizer in 2010. Sonedenoson has been in phase II clinical trials for the treatment of chronic diabetic neuropathic foot ulcers. However, this research has been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Design and application of locally delivered agonists of the adenosine A(2A) receptor.	2010-01	22111533
Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis.	2006-08	16783407

Patents

Sample Use Guides

In Vivo Use Guide

Application of Sonedenoson (MRE0094) (1 ug/wound and 10 ug/wound) achieved 50% wound closure significantly more rapidly than control application (day 1.9, 1.9, 3.5, 3.2, respectively, versus control day 4).

Route of Administration: Topical

In Vitro Use Guide

TSP1 protein secretion was down-regulated after treatment with the A2A agonist in a dose-dependent manner (EC50 = 0.23 uM).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:30:27 GMT 2025` Edited by `admin` on `Mon Mar 31 18:30:27 GMT 2025`
Record UNII	2OT4KAG5JL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SONEDENOSON

Official Name

English

MRE-0094

Preferred Name

English

ADENOSINE, 2-(2-(4-CHLOROPHENYL)ETHOXY)-

Systematic Name

English

SONEDENOSON [USAN]

Common Name

English

Sonedenoson [WHO-DD]

Common Name

English

MRE0094

Code

English

9-.BETA.-D-RIBOFURANOSYL-2-(2-(4-CHLOROPHENYL)ETHOXY)-9H-PURIN-6-AMINE

Common Name

English

sonedenoson [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29707